A prognostic nomogram for prediction of recurrence in desmoid fibromatosis

Annals of Surgery

Volumn 258, Issue 2, 2013, Pages 347-353

  Crago, Aimeé M ^a   Denton, Brian ^b   Salas, Sébastien ^c   Dufresne, Armelle ^d   Mezhir, James J ^a   Hameed, Meera ^b   Gonen, Mithat ^b   Singer, Samuel ^a   Brennan, Murray F ^a  

^a Biostatist Epidemiol St Jude C   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c University of the Mediterranean Aix Marseille II   (France)

^d CENTRE LÉON BÉRARD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABDOMINAL WALL DEFECT; ADOLESCENT; ADULT; AGED; ARTICLE; AXILLA; BUTTOCK; CANCER RADIOTHERAPY; CHEMOTHERAPY; CONTROLLED STUDY; DESMOID TUMOR; FEMALE; FIBROMATOSIS; FOLLOW UP; HUMAN; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; PATIENT COUNSELING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; RIB; RISK ASSESSMENT; SHOULDER; SOFT TISSUE SARCOMA; TUMOR LOCALIZATION; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DECISION SUPPORT TECHNIQUES; FEMALE; FIBROMATOSIS, AGGRESSIVE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NOMOGRAMS; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84880570925     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31828c8a30     Document Type: Article

References (31)

1. Wu C, Nik-Amini S,Nadesan P, et al.Aggressive fibromatosis (desmoid tumor) is derived from mesenchymal progenitor cells. Cancer Res. 2010;70:7690-7698.
2. Li M, Cordon-Cardo C, Gerald WL, et al. Desmoid fibromatosis is a clonal process. Hum Pathol. 1996;27:939-943.
3. Alman BA, Li C, Pajerski ME, et al. Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). Am J Pathol. 1997;151:329-334.
4. Li C, Bapat B, Alman BA. Adenomatous polyposis coli gene mutation alters proliferation through its beta-catenin-regulatory function in aggressive fibromatosis (desmoid tumor). Am J Pathol. 1998;153:709-714.
5. Tejpar S, Nollet F, LiC, et al. Predominance of beta-catenin mutations and betacatenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene. 1999;18:6615-6620.
6. Lazar AJ, Tuvin D, Hajibashi S, et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol. 2008;173:1518-1527.
7. Robanus-Maandag E, Bosch C, Amini-Nik S, et al. Familial adenomatous polyposis-associated desmoids display significantlymore genetic changes than sporadic desmoids. PLoS One. 2011;6:e24354.
8. Lewis JJ, Boland PJ, Leung DH, et al. The enigma of desmoid tumors. Ann Surg. 1999;229:866-872; discussion 872-873.
9. Merchant NB, Lewis JJ, Woodruff JM, et al. Extremity and trunk desmoid tumors: A multifactorial analysis of outcome. Cancer. 1999;86:2045-2052.
10. Easter DW, Halasz NA. Recent trends in the management of desmoid tumors. Summary of 19 cases and review of the literature. Ann Surg. 1989;210:765-769.
11. Higaki S, Tateishi A, Ohno T, et al. Surgical treatment of extra-abdominal desmoid tumours (aggressive fibromatoses). Int Orthop. 1995;19:383-389.
12. Lopez R, Kemalyan N, Moseley HS, et al. Problems in diagnosis and management of desmoid tumors. Am J Surg. 1990;159:450-453.
13. Markhede G, Lundgren L, BjurstamN, et al. Extra-abdominal desmoid tumors. Acta Orthop Scand. 1986;57:1-7.
14. Plukker JT, van Oort I, Vermey A, et al. Aggressive fibromatosis (non-familial desmoid tumour): Therapeutic problems and the role of adjuvant radiotherapy. Br J Surg. 1995;82:510-514.
15. Rock MG, Pritchard DJ, Reiman HM, et al. Extra-abdominal desmoid tumors. J Bone Joint Surg Am. 1984;66:1369-1374.
16. Fiore M, Rimareix F, Mariani L, et al. Desmoid-type fibromatosis: A frontline conservative approach to select patients for surgical treatment. Ann Surg Oncol. 2009;16:2587-2593.
17. Smith AJ, Lewis JJ, Merchant NB, et al. Surgical management of intraabdominal desmoid tumours. Br J Surg. 2000;87:608-613.
18. de Camargo VP, Keohan ML, D'Adamo DR, et al. Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). Cancer. 2010;116:2258-2265.
19. Gounder MM, Lefkowitz RA, Keohan ML, et al. Activity of sorafenib against desmoid tumor/deep fibromatosis. Clin Cancer Res. 2011;17:4082-4090.
20. Salas S, Dufresne A, Bui B, et al. Prognostic factors influencing progressionfree survival determined from a series of sporadic desmoid tumors: A wait-andsee policy according to tumor presentation. J Clin Oncol. 2011;29:3553-3558.
21. Kattan MW, Leung DH, Brennan MF. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol. 2002;20:791-796.
22. Canter RJ, Qin LX, Maki RG, et al. A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients. Clin Cancer Res. 2008;14: 8191-8197.
23. Dalal KM, Kattan MW, Antonescu CR, et al. Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg. 2006;244:381-391.
24. Brennan MF, Kattan MW, Klimstra D, et al. Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann Surg. 2004;240:293-298.
25. Wong SL, Kattan MW, McMasters KM, et al. A nomogram that predicts the presence of sentinel node metastasis in melanoma with better discrimination than theAmerican Joint Committee on Cancer staging system. Ann SurgOncol. 2005;12:282-288.
26. Barlin JN, Yu C, Hill EK, et al. Nomogram for predicting 5-year diseasespecific mortality after primary surgery for epithelial ovarian cancer. Gynecol Oncol. 2012;125:25-30.
27. Weiser MR, Gonen M, Chou JF, et al. Predicting survival after curative colectomy for cancer: Individualizing colon cancer staging. J Clin Oncol. 2011;29:4796-4802.
28. Guadagnolo BA, Zagars GK, Ballo MT. Long-term outcomes for desmoid tumors treated with radiation therapy. Int J RadiatOncol Biol Phys. 2008;71:441-447.
29. Jelinek JA, Stelzer KJ,Conrad E, et al. The efficacy of radiotherapy as postoperative treatment for desmoid tumors. Int J RadiatOncol Biol Phys. 2001;50:121-125.
30. Ballo MT, Zagars GK, Pollack A, et al. Desmoid tumor: Prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol. 1999;17:158-167.
31. Lev D, Kotilingam D, Wei C, et al. Optimizing treatment of desmoid tumors. J Clin Oncol. 2007;25:1785-1791.